by | Jul 4, 2024 | Publications
Blood. 2024 Jul 4;144(1):124. doi: 10.1182/blood.2024025297. NO ABSTRACT PMID:38963667 | DOI:10.1182/blood.2024025297
by | Jul 4, 2024 | Publications
Clin Case Rep. 2024 Jul 3;12(7):e9154. doi: 10.1002/ccr3.9154. eCollection 2024 Jul. ABSTRACT Down syndrome (DS), characterized by trisomy 21, significantly increases susceptibility to leukemia, although the occurrence of multiple myeloma (MM) in DS is exceedingly...
by | Jul 4, 2024 | Publications
Int J Lab Hematol. 2024 Jul 3. doi: 10.1111/ijlh.14337. Online ahead of print. ABSTRACT INTRODUCTION: Autologous hematopoietic stem cell transplantation (ASCT) has gained extensive application in the treatment of lymphoma and multiple myeloma (MM). Plenty of studies...
by | Jul 4, 2024 | Publications
Mol Biomed. 2024 Jul 4;5(1):25. doi: 10.1186/s43556-024-00188-w. ABSTRACT Multiple myeloma (MM) is the second most common hematological malignancy of plasma cells, characterized by osteolytic bone lesions, anemia, hypercalcemia, renal failure, and the accumulation of...
by | Jul 4, 2024 | Publications
Nat Rev Clin Oncol. 2024 Jul 3. doi: 10.1038/s41571-024-00913-y. Online ahead of print. ABSTRACT A better understanding of the roles of the adaptive and innate immune systems in the oncogenesis of cancers including multiple myeloma (MM) has led to the development of...
by | Jul 4, 2024 | Publications
Mutat Res. 2024 Jun 18;829:111869. doi: 10.1016/j.mrfmmm.2024.111869. Online ahead of print. ABSTRACT BACKGROUND: Multiple myeloma cancer stem cells (MMSC) have been considered as the leading cause of multiple myeloma (MM) drug resistance and eventual relapse,...
